Denali Therapeutics Inc (DNLI)

04:10 AM

What Happened To Denali Therapeutics Stock Wednesday? - Benzinga

04:10 AM

03:59 AM

Sector Update: Health Care Stocks Advance in Late Afternoon Trading - TradingView

03:59 AM

03:49 AM

Sector Update: Health Care - MarketScreener

03:49 AM

11:48 AM

Denali Therapeutics begins marketing application for genetic disorder drug, shares rise - TradingView

11:48 AM

10:39 AM

How another firm's FDA approval could mean a big win for Denali Therapeutics - The Business Journals

10:39 AM

10:38 AM

Denali Therapeutics Files Application for Accelerated Approval of Hunter Syndrome Treatment; Shares Up - MarketScreener

10:38 AM

09:03 AM

Denali Therapeutics advances Hunter syndrome treatment BLA - Investing.com India

09:03 AM

08:02 AM

Denali Therapeutics Announces Initiation of BLA Filing for - GlobeNewswire

08:02 AM

08:00 AM

Breakthrough: Denali's Hunter Syndrome Drug Enters Final FDA Approval Stage - Stock Titan

08:00 AM

Mar 30, 2025

Trend Tracker for (DNLI) - news.stocktradersdaily.com

Mar 30, 2025

Mar 26, 2025

Denali Therapeutics stock hits 52-week low at $13.95 By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

Denali Therapeutics stock hits 52-week low at $13.95 - Investing.com India

Mar 26, 2025

Mar 21, 2025

Exponential Growth Expected for Blood Brain Barrier Market With - openPR.com

Mar 21, 2025

Mar 20, 2025

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead (NASDAQ:DNLI) - Seeking Alpha

Mar 20, 2025

Mar 20, 2025

Why You Shouldn't Bet Against Denali (DNLI) Stock - Barchart

Mar 20, 2025

Mar 20, 2025

(DNLI) On The My Stocks Page - news.stocktradersdaily.com

Mar 20, 2025

Mar 19, 2025

Denali Starts Dosing in Phase II Parkinson's Disease Study - MSN

Mar 19, 2025

Mar 13, 2025

Denali halts extension of DNL343 arm in HEALEY ALS trial - ALS News Today

Mar 13, 2025

Mar 11, 2025

Denali Therapeutics (NASDAQ:DNLI) Given New $28.00 Price Target at Bank of America - Defense World

Mar 11, 2025

Mar 11, 2025

Denali Therapeutics (NASDAQ:DNLI) Shares Down 8.9% on Analyst Downgrade - Defense World

Mar 11, 2025

Mar 10, 2025

Why Denali Therapeutics Shares Are Tumbling - TipRanks

Mar 10, 2025

Mar 10, 2025

Bank of New York Mellon Corp Decreases Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World

Mar 10, 2025

Mar 10, 2025

Proficio Capital Partners LLC Makes New $514,000 Investment in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World

Mar 10, 2025

Mar 10, 2025

Denali Therapeutics (NASDAQ:DNLI) Earns Overweight Rating from Analysts at Morgan Stanley - Defense World

Mar 10, 2025

Mar 09, 2025

How the (DNLI) price action is used to our Advantage - Stock Traders Daily

Mar 09, 2025

Mar 08, 2025

B. Riley Forecasts Lower Earnings for Denali Therapeutics - Defense World

Mar 08, 2025

Mar 07, 2025

Denali's ALS programme suffers another setback - pharmaphorum

Mar 07, 2025

Mar 07, 2025

What is B. Riley’s Forecast for DNLI FY2029 Earnings? - Defense World

Mar 07, 2025

Mar 07, 2025

B. Riley Reaffirms Buy Rating for Denali Therapeutics (NASDAQ:DNLI) - Defense World

Mar 07, 2025

Mar 06, 2025

Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback - Benzinga India

Mar 06, 2025

Mar 05, 2025

Denali Therapeutics discontinues active treatment extension in eIF2B Regimen G - TipRanks

Mar 05, 2025

Mar 05, 2025

Denali Therapeutics Discontinues DNL343 ALS Trial - TipRanks

Mar 05, 2025

Mar 05, 2025

DNLI stock touches 52-week low at $14.55 amid market challenges - Investing.com Australia

Mar 05, 2025

Mar 05, 2025

B. Riley Trims Price Target on Denali Therapeutics to $35 From $38, Keeps Buy Rating - Marketscreener.com

Mar 05, 2025

Mar 05, 2025

Denali Therapeutics (NASDAQ:DNLI) Sets New 12-Month Low Following Analyst Downgrade - Defense World

Mar 05, 2025

Mar 04, 2025

DNLI stock touches 52-week low at $14.55 amid market challenges By Investing.com - Investing.com South Africa

Mar 04, 2025

Mar 04, 2025

Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer - Yahoo Finance

Mar 04, 2025

Mar 03, 2025

Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025? - Insider Monkey

Mar 03, 2025

Mar 03, 2025

Oppenheimer Adjusts Denali Therapeutics Price Target to $42 From $50, Maintains Outperform Rating - Marketscreener.com

Mar 03, 2025

Mar 03, 2025

Deutsche Bank Adjusts Denali Therapeutics Price Target to $29 From $31, Maintains Buy Rating - Marketscreener.com

Mar 03, 2025

Mar 03, 2025

Denali Therapeutics: Why Analysts Remain Optimistic - TipRanks

Mar 03, 2025

Mar 03, 2025

Denali Therapeutics’ (DNLI) “Outperform” Rating Reiterated at William Blair - Defense World

Mar 03, 2025

Mar 03, 2025

What is HC Wainwright’s Forecast for DNLI Q1 Earnings? - Defense World

Mar 03, 2025

Mar 03, 2025

Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $87.00 - Defense World

Mar 03, 2025

Mar 02, 2025

Denali Q4 Earnings Beat Estimates, Hunter Syndrome Drug in Focus - MSN

Mar 02, 2025

Mar 02, 2025

Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In - Insider Monkey

Mar 02, 2025

Mar 01, 2025

Y Intercept Hong Kong Ltd Has $734,000 Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat

Mar 01, 2025

Mar 01, 2025

William Blair Reiterates "Outperform" Rating for Denali Therapeutics (NASDAQ:DNLI) - MarketBeat

Mar 01, 2025

Feb 28, 2025

Denali Therapeutics closes down 11% as 2025 operating expenses seen weighing - MSN

Feb 28, 2025

Feb 28, 2025

Denali Therapeutics (NASDAQ:DNLI) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat

Feb 28, 2025

Feb 28, 2025

Wedbush Adjusts Price Target on Denali Therapeutics to $32 From $33, Maintains Outperform Rating - Marketscreener.com

Feb 28, 2025

Feb 28, 2025

Positive Outlook for Denali Therapeutics: Strategic Progress and Promising Developments Support Buy Rating - TipRanks

Feb 28, 2025